Convexia (YC S25)
Convexia accelerates the sourcing and evaluation of overlooked drug assets so buyers can identify licensable candidates faster. It runs an AI-native agent stack that automates sourcing, in-silico modeling, and commercial diligence, including over 50 custom models for binding, toxicity, ADME/PK, plus clinical profiling and safety prediction. The platform packages high-potential molecules for licensing and operates via licensing and pilot engagements with pharma, biotech, and investment groups. Convexia is an AI-driven B2B platform aiming to replace months of manual diligence and ultimately manage more of the drug lifecycle.
Convexia (YC S25)
Convexia accelerates the sourcing and evaluation of overlooked drug assets so buyers can identify licensable candidates faster. It runs an AI-native agent stack that automates sourcing, in-silico modeling, and commercial diligence, including over 50 custom models for binding, toxicity, ADME/PK, plus clinical profiling and safety prediction. The platform packages high-potential molecules for licensing and operates via licensing and pilot engagements with pharma, biotech, and investment groups. Convexia is an AI-driven B2B platform aiming to replace months of manual diligence and ultimately manage more of the drug lifecycle.